Investing.com - CureVac NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
CureVac NV announced earnings per share of €-0.25 on revenue of €11.2M. Analysts polled by Investing.com anticipated EPS of €-0.27 on revenue of €20.33M.
CureVac NV shares are down 76% from the beginning of the year and are trading at €8.00 , down-from-52-week-high.
CureVac NV follows other major Healthcare sector earnings this month
CureVac NV's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of €1.98 on revenue of €6.94B, compared to forecasts EPS of €1.91 on revenue of €6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of €1.78 on revenue of €22.6B, compared to forecast for EPS of €1.44 on revenue of €21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar